company background image
BOI logo

Boiron ENXTPA:BOI Stock Report

Last Price

€29.90

Market Cap

€519.1m

7D

-5.5%

1Y

-24.7%

Updated

20 Nov, 2024

Data

Company Financials +

Boiron SA

ENXTPA:BOI Stock Report

Market Cap: €519.1m

BOI Stock Overview

Manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. More details

BOI fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance1/6
Financial Health6/6
Dividends2/6

Rewards

Trading at 74.1% below our estimate of its fair value

Earnings are forecast to grow 26.21% per year

Risk Analysis

Dividend of 4.52% is not well covered by earnings or free cash flows

Large one-off items impacting financial results

Profit margins (4.9%) are lower than last year (9.2%)


Boiron SA Competitors

Vetoquinol

ENXTPA:VETO

€933.6m

Virbac

ENXTPA:VIRP

€2.7b

Ipsen

ENXTPA:IPN

€8.8b

Sanofi

ENXTPA:SAN

€113.8b

Price History & Performance

Summary of all time highs, changes and price drops for Boiron
Historical stock prices
Current Share Price€29.90
52 Week High€42.80
52 Week Low€29.15
Beta0.45
11 Month Change-8.70%
3 Month Change-6.12%
1 Year Change-24.69%
33 Year Change-21.32%
5 Year Change-11.80%
Change since IPO546.91%

Recent News & Updates

Recent updates

Calculating The Intrinsic Value Of Boiron SA (EPA:BOI)

Jan 26
Calculating The Intrinsic Value Of Boiron SA (EPA:BOI)

Boiron (EPA:BOI) Has Re-Affirmed Its Dividend Of €0.95

Apr 28
Boiron (EPA:BOI) Has Re-Affirmed Its Dividend Of €0.95

Estimating The Intrinsic Value Of Boiron SA (EPA:BOI)

Jan 22
Estimating The Intrinsic Value Of Boiron SA (EPA:BOI)

Is Boiron SA's (EPA:BOI) 2.3% Dividend Worth Your Time?

Apr 30
Is Boiron SA's (EPA:BOI) 2.3% Dividend Worth Your Time?

Boiron (EPA:BOI) Has A Pretty Healthy Balance Sheet

Apr 12
Boiron (EPA:BOI) Has A Pretty Healthy Balance Sheet

Reflecting on Boiron's (EPA:BOI) Share Price Returns Over The Last Three Years

Mar 08
Reflecting on Boiron's (EPA:BOI) Share Price Returns Over The Last Three Years

A Look At The Intrinsic Value Of Boiron SA (EPA:BOI)

Feb 18
A Look At The Intrinsic Value Of Boiron SA (EPA:BOI)

Does The Market Have A Low Tolerance For Boiron SA's (EPA:BOI) Mixed Fundamentals?

Feb 02
Does The Market Have A Low Tolerance For Boiron SA's (EPA:BOI) Mixed Fundamentals?

Should You Buy Boiron SA (EPA:BOI) For Its Dividend?

Jan 19
Should You Buy Boiron SA (EPA:BOI) For Its Dividend?

Does Boiron's (EPA:BOI) Statutory Profit Adequately Reflect Its Underlying Profit?

Dec 27
Does Boiron's (EPA:BOI) Statutory Profit Adequately Reflect Its Underlying Profit?

What Kind Of Shareholders Hold The Majority In Boiron SA's (EPA:BOI) Shares?

Dec 14
What Kind Of Shareholders Hold The Majority In Boiron SA's (EPA:BOI) Shares?

Shareholder Returns

BOIFR PharmaceuticalsFR Market
7D-5.5%-3.4%-0.3%
1Y-24.7%6.2%-3.5%

Return vs Industry: BOI underperformed the French Pharmaceuticals industry which returned 6.2% over the past year.

Return vs Market: BOI underperformed the French Market which returned -2.5% over the past year.

Price Volatility

Is BOI's price volatile compared to industry and market?
BOI volatility
BOI Average Weekly Movement3.3%
Pharmaceuticals Industry Average Movement3.7%
Market Average Movement4.5%
10% most volatile stocks in FR Market9.2%
10% least volatile stocks in FR Market2.2%

Stable Share Price: BOI has not had significant price volatility in the past 3 months compared to the French market.

Volatility Over Time: BOI's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19322,788Thierry Boironwww.boiron.fr

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products include medical devices, invitro diagnostics, dietary supplements, cosmetics, and phytotherapy. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; Sédatif PC to treat anxiety and emotional, and minor sleep disorders; Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; Homéovox for vocal disorders; Homéoplasmine for treating irritated skin and redness; Varésol to treat symptoms of chickenpox; and Arnicare Arthritis for use in the treatment of benign trauma pain.

Boiron SA Fundamentals Summary

How do Boiron's earnings and revenue compare to its market cap?
BOI fundamental statistics
Market cap€519.13m
Earnings (TTM)€23.69m
Revenue (TTM)€481.71m

21.9x

P/E Ratio

1.1x

P/S Ratio

Is BOI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BOI income statement (TTM)
Revenue€481.71m
Cost of Revenue€130.85m
Gross Profit€350.87m
Other Expenses€327.18m
Earnings€23.69m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)1.36
Gross Margin72.84%
Net Profit Margin4.92%
Debt/Equity Ratio1.1%

How did BOI perform over the long term?

See historical performance and comparison

Dividends

4.5%

Current Dividend Yield

99%

Payout Ratio